Scott Juda is Director at Inmune Bio, Inc. (INMB). They have made 6 open-market trades across 1 company since 2019, most recently 2026-07-02.
CIK 0001767084
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
6 open-market purchases totalling $455K since 2019, never a sale. Across 6 scored buys the stock is down 12.8% at ninety days, and 18.3 points behind the S&P over the same stretch.
6 scored purchases · one row per filing · discretionary only
| Ticker | Shares | Value |
|---|---|---|
| INMB | 86,404 | $136K |
Shares reported on the most recent Form 4, priced at the 2026-07-07 close.
| 7d | 30d | 90d | |
|---|---|---|---|
| Accuracy | 67% | 33% | 17% |
| Avg Move | +6.3% | +2.7% | -12.8% |
| Alpha | +4.9% | -0.2% | -18.3% |
| Scored | 6 | 6 | 6 |
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| INMB | BUY | 2024-06-25 | 2024-06-26 | $7.27 | $36K | +2.9% | +13.2% | -32.5% |
| INMB | BUY | 2024-04-19 | 2024-04-24 | $8.32 | $246K | +10.1% | -0.6% | -16.8% |
| INMB | BUY | 2023-11-10 | 2023-11-13 | $6.95 | $49K | +25.5% | +42.0% | +67.0% |
| INMB | BUY | 2021-11-17 | 2021-11-17 | $13.55 | $34K | -6.0% | -21.0% | -21.8% |
| INMB | BUY | 2019-08-20 | 2019-08-22 | $6.00 | $30K | +5.2% | -9.2% | -30.3% |
| INMB | BUY | 2019-06-03 | 2019-06-04 | $6.00 | $60K | -0.1% | -8.3% | -42.7% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.